The portfolio consists of acute, chronic and oncology products.
MUMBAI: Homegrown Aurobindo Pharma, Zydus Cadila, Torrent Pharma and Intas have expressed preliminary interest in buying the European generics business of Paris-headquartered pharma giant Sanofi as frenzied dealmaking continues in Big Pharma the world over in the new year.
The portfolio of acute, chronic and oncology products could fetch a valuation of $1.5-2 billion, making it among the largest outbound transactions pursued by an Indian drug company, said multiple sources.
